Jenkins Casey A. Files SC 13D for Catheter Precision

TL;DR

**Jenkins Casey A. just filed a 13D on Catheter Precision (CPTR). Big ownership change incoming.**

AI Summary

On August 30, 2024, Jenkins Casey A. filed a Schedule 13D for Catheter Precision, Inc. (formerly Ra Medical Systems, Inc.). This filing indicates a change in beneficial ownership, with Jenkins Casey A. now holding a significant stake in the company. The filing was made with the SEC and pertains to the common stock of Catheter Precision, Inc.

Why It Matters

This filing signals a potential shift in control or influence over Catheter Precision, Inc. by a significant shareholder, which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or changes in control, which can introduce volatility.

Key Players & Entities

• Jenkins Casey A. (person) — Filing person
• Catheter Precision, Inc. (company) — Subject company
• Ra Medical Systems, Inc. (company) — Former company name
• August 30, 2024 (date) — Date of event requiring filing

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securitie
• $500,000 — or Other Consideration Approximately $500,000 of funds held by the Jenkins Family Cha
• $1.00 — t, priced at a public offering price of $1.00 per unit, consisted of one share of com
• $0.9999 — t, priced at a public offering price of $0.9999 per unit, consisted of one pre-funded w

Filing Documents

• rmed_424b1.htm (SC 13D) — 68KB
• 0001654954-24-011641.txt ( ) — 70KB

Security and Issuer

Item 1. Security and Issuer This Schedule 13D relates to the common stock, $0.0001 par value per share (the "Common Stock"), of Catheter Precision, Inc., a Delaware corporation (the "Company"). The principal executive office of the Company is located at: 1670 Highway 160 West Suite 205 Fort Mill, SC 29708

Identity and Background

Item 2. Identity and Background 1. The Jenkins Family Charitable Institute is a reporting person filing this statement. It is a private foundation, and its principal business address is 225 Franz Valley School Road, Calistoga, CA 94515. 2. Its principal business is to serve as a family charitable entity. (d) None. (e) None. 2. (a) Casey A. Jenkins is a reporting person filing this statement and is the trustee of the Jenkins Family Charitable Institute, which is a reporting person filing this statement. (b) 225 Franz Valley School Road, Calistoga, CA 94515. (c) Ms. Jenkins is the Vineyard Manager for Heritage School Vineyards, LLC. (d) None. (e) None. (f) United States.

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration Approximately $500,000 of funds held by the Jenkins Family Charitable Institute (the "Institute") were used to purchase 265,000 common stock units and 235,000 pre-funded units of the Company in an underwritten public offering (the "Public Offering") pursuant to an underwriting agreement dated August 30, 2024. Each common stock unit, priced at a public offering price of $1.00 per unit, consisted of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the six month anniversary of the date of issuance (a "Series H Warrant"), one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the eighteen month anniversary of the date of issuance (a "Series I Warrant"), and one warrant to purchase one share of common stock at an exercise price of $1.00 per share that expires on the five year anniversary of the date of issuance (a "Series J Warrant"). Each pre-funded unit, priced at a public offering price of $0.9999 per unit, consisted of one pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001 per share that has no expiration date (a "Pre-Funded Warrant" and together with the Series H Warrants, Series I Warrants and Series J Warrants, the "Warrants"), one Series H Warrant, one Series I Warrant and one Series J Warrant. The Public Offering closed on September 3, 2024. Each of the Warrants contains a beneficial ownership blocker that currently prevents the Institute from exercising it to acquire additional shares of common stock. CUSIP No 74933X 609 Page 5 of 8

Purpose of Transaction

Item 4. Purpose of Transaction All acquisitions described in Item 3 above and Item 5 below were for investment purposes. The reporting persons may make additional open market purchases or sales or engage in estate planning or other transactions in Company common stock, from time to time. The reporting persons have no present intent to take any action that would result in: (a) the acquisition by any person of additional securities of the Company or the disposition of securities of the Company; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any subsidiary thereof; (c) a sale or transfer of a material amount of assets of the Company or any subsidiary thereof; (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) any material change in the present capitalization or dividend policy of the Company; (f) any other material change in the Company's business or corporate structure; (g) any changes in the Company's charter, bylaws, or instruments corresponding thereto, or other actions which may impede the acquisition of control of the Company by any person; (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (j) any action similar to any of those enumerated above.

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer (a)-(b) See the cover pages to this Amendment. (c) The following transactions were effected by the reporting persons within 60 days prior to the date hereof: See Item 3 above. CUSIP No 74933X 609 Page 6 of 8 There were no other transactions in Company common stock effected by the reporting persons or the other persons listed in Item 2 within 60 days of the date hereof. (d) None. (e) Not applicable.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer See Item 3 above. There are no other contracts, arrangements, understandings, or relationships with respect to any securities of the Company, including but not limited to transfer or voting of any of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss or the giving or withholding of proxies.

Material to be Filed as Exhibits

Item 7. Material to be Filed as Exhibits Exhibit No. Description 1.1 Underwriting Agreement dated as of August 30, 2024, by and between Catheter Precision, Inc. and Ladenburg Thalmann & Co. Inc., as Representative of the Underwriters (incorporated by reference to Exhibit 1.1 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) 4.1 Series H Warrant (incorporated by reference to Exhibit 4.1 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) 4.2 Series I Warrant (incorporated by reference to Exhibit 4.2 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) 4.3 Series J Warrant (incorporated by reference to Exhibit 4.3 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) 4.4 Pre-Funded Warrant (incorporated by reference to Exhibit 4.4 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) 4.5 Warrant Agency Agreement dated September 3, 2024, by and between Catheter Precision, Inc. and Equiniti Trust Company, LLC (incorporated by reference to Exhibit 4.5 of Company's Report on Form 8-K filed on September 6, 2024, 2024 (File No. 001-38677)) CUSIP No 74933X 609 Page 7 of 8 Signature. After reasonable inquiry each of the undersigned certifies that to the best of his or her knowledge and belief the information set forth in this statement is true, complete and correct. JENKINS FAMILY CHARITABLE INSTITUTE By: /s/ Casey A Jenkins Date: September 9, 2024 Casey A. Jenkins, Trustee /s/ Casey A. Jenkins Date: September 9, 2024 CASEY A. JENKINS Page 8 of 8 EXHIBIT A The undersigned each hereby certifies and agrees that the above Amendment to Schedule 13D concerning securities issued by Catheter Precision, Inc. is being filed on behalf of each of the undersigned. JENKINS FAMILY CHARITABLE INSTITUTE By: /s/ Casey A Jenkins Date: September 9, 2024 Casey A. Jenkins, Trustee /s

View Full Filing

View this SC 13D filing on SEC EDGAR